Ovarian cancer causes more deaths than any other cancer of the female reproductive system, but it accounts for only about 3% of all cancers in women. Early and accurate diagnosis of ovarian cancer will improve survival, as treatment works best when cancer is detected in its early stages.
InterVenn is developing a first-in-class mass spec-based glycoproteomic clinical diagnostic test for ovarian cancer. Currently undergoing clinical validation in a global, multi-center clinical trial, this proprietary test will enable clinicians to distinguish benign from malignant masses in women presenting with adnexal (pelvic) masses, through a simple blood test.
Learn more about participating in the VOCAL trial at ClinicalTrials.gov (NCT03837327).